Results 21 to 30 of about 29,662,057 (278)

The role of sodium-glucose co-transporter-2 inhibitors in frail older adults with or without type 2 diabetes mellitus [PDF]

, 2022
Sodium-glucose co-transporter-2 (SGLT2) inhibitors offer significant outcome benefits beyond glucose lowering including reduced risk of cardiovascular death, all-cause mortality, major adverse cardiovascular events, hospitalisations for heart failure and
M Evans (7332128), S Davies (6285992), AR Morgan (7776470), H Beba (21944267), WD Strain (14423826)   +4 more
core   +6 more sources

Sodium-glucose co-transporter-2 inhibitors and epicardial adiposity

Epicardial adipose tissue is a layer of adipocytes that physiologically surround the myocardium and play some physiologic roles in normal heart function.
Mina Maleki (5990621), Amirhossein Sahebkar (10910734), Tannaz Jamialahmadi (11177065), Alexandra Butler (13855088), Habib Yaribeygi (13932315)   +4 more
core   +4 more sources

Sodium-glucose co-transporter-2 inhibitors in patients treated with immune checkpoint inhibitors

Cardio-Oncology
Background Immune checkpoint inhibitors (ICIs) have revolutionized the prognosis of cancer. Diabetes mellitus (DM) has been shown to have a negative effect on patients treated with ICIs.
Moran Gvili Perelman, Rafael Y. Brzezinski, Barliz Waissengrin, Yasmin Leshem, Or Bainhoren, Tammi Arbel Rubinstein, Maxim Perelman, Zach Rozenbaum, Ofer Havakuk, Yan Topilsky, Shmuel Banai, Ido Wolf, Michal Laufer-Perl   +12 more
doaj   +3 more sources

Harms and benefits fo sodium-glucose co-transporter 2 inhibitors [PDF]

Australian Prescriber, 2020
Sodium-glucose co-transporter 2 inhibitors are oral glucose-lowering drugs that increase the urinary excretion of glucose. In patients with type 2 diabetes and cardiovascular disease they reduce all-cause mortality, cardiac mortality, rates of hospitalisation for heart failure and the progression of renal disease There are adverse effects related to ...
Chesterman, Thomas, Thynne, Tilenka RJ
openaire   +2 more sources

A review of the safety of sodium-glucose co-transporter-2 inhibitors. [PDF]

Diabetes Obes Metab
Abstract The development of sodium‐glucose co‐transporter‐2 (SGLT2) inhibitors represents a major turning point in the effort to preserve kidney function and prevent cardiovascular events and heart failure hospitalisations in those at high risk. These agents have now transcended their original glucose‐lowering indication and provide a
O'Hara DV, Jardine MJ.
europepmc   +3 more sources

Safety of Sodium-Glucose Co-Transporter 2 Inhibitors [PDF]

The American Journal of Cardiology, 2019
Sodium-glucose co-transporter 2 (SGLT2) inhibitors have a well-defined safety profile based on data obtained from numerous clinical trials, including cardiovascular outcomes trials (CVOTs) and postmarketing pharmacovigilance reporting. Adverse events including risk of genital mycotic infection and volume depletion-related events are consistent with the
Janet B. McGill, Savitha Subramanian
openaire   +3 more sources

Sodium-glucose co-transporter-2 inhibitors and epicardial adiposity

European Journal of Pharmaceutical Sciences, 2023
Epicardial adipose tissue is a layer of adipocytes that physiologically surround the myocardium and play some physiologic roles in normal heart function. However, in pathologic conditions, the epicardial adipose tissue can present a potent cardiac risk factor that is capable of impairing heart function through several pathways, increasing the risk of ...
Habib Yaribeygi, Mina Maleki, Alexandra E. Butler, Tannaz Jamialahmadi, Amirhossein Sahebkar   +4 more
openaire   +2 more sources

Sodium-Glucose Co-Transporter 2 Inhibitors and Fracture Risk [PDF]

Diabetes Therapy, 2019
Patients with type 2 diabetes mellitus (T2DM) appear to have increased risk for fractures. In this context, the finding that canagliflozin, a sodium-glucose co-transporter-2 (SGLT) inhibitor, increased the risk for fracture compared with placebo in the Canagliflozin Cardiovascular Assessment Study (CANVAS), a large randomized controlled trial (RCT) in ...
Anastasia Erythropoulou-Kaltsidou, Georgios Polychronopoulos, Konstantinos Tziomalos   +2 more
openaire   +2 more sources

Sodium glucose co-transport 2 inhibitors for gout treatment

Discoveries, 2022
Hyperuricemia remains the most prevalent cause of gout. Gout patients present with joint inflammation and uric acid crystals deposition manifesting as tophi. The association of gout with increased risk of insulin resistance, diabetes, metabolic disorders, increased cardiometabolic risk, and kidney disease is well established.
Somagutta, Manoj Kumar Reddy, Luvsannyam, Enkhmaa, Jain, Molly, Cuddapah, Gaurav Venkat, Pelluru, Sandeep, Mustafa, Nafisa, Nasereldin, Duaa S., Pendyala, Siva K., Jarapala, Nagendrababu, Padamati, Bhavani   +9 more
openaire   +2 more sources

The Evolution of Sodium-Glucose Co-Transporter-2 Inhibitors in Heart Failure [PDF]

Cureus, 2021
Sodium-glucose co-transporter-2 (SGLT2) inhibitors have evolved over the years, based on data from several randomized, double-blinded, placebo-controlled clinical trials. Formerly used primarily for blood sugar control in patients with diabetes, they are now used to decrease the risk of hospitalization for heart failure (HF), or of death from ...
Fadiran, Olusayo, Nwabuo, Chike
openaire   +2 more sources